CEP290: A Tumor Antigen and Potential Drug Target (G80184)

Target Name: CEP290

NCBI ID: G80184

CEP290

CEP290: A Tumor Antigen and Potential Drug Target

Introduction

CEP290, also known as SE2-2, is a tumor antigen that has been identified in various types of cancer, including breast, ovarian, and colorectal cancer. Its unique structure and expression pattern have made it an attractive target for researchers to investigate in the fight against cancer. In this article, we will discuss the biology of CEP290, its potential as a drug target, and the ongoing research in this field.

biological background

CEP290 is a tumor antigen expressed in a variety of cancers, including breast, ovarian, and rectal cancer. Its unique structure and expression pattern make it an important target for cancer treatment research. In this article, we will discuss the biological background of CEP290, its potential as a drug target, and current research progress.

Expression of CEP290

The expression levels of CEP290 vary in different types of cancer. In some tumors, CEP290 expression levels are high, while in others they are low. However, even among different types of tumors, the expression levels of CEP290 show some overlap. This suggests that CEP290 may play similar roles in different types of tumors and serve as a potential drug target.

Structure and function of CEP290

CEP290 is a protein with a complex structure. It has a molecular weight of approximately 300 kDa and consists of two major polypeptide chains: the N-terminal 伪 chain and the C-terminal 尾 chain. The alpha chain of CEP290 consists of 114 amino acids, while the beta chain consists of 101 amino acids.

Both the 伪 and 尾 chains of CEP290 have highly conserved sequences, indicating its stability in tumors. In addition, there are some similar functional regions between the 伪 chain and 尾 chain of CEP290, such as the tumor antigen receptor (TAR) binding site on the 伪 chain and the cell adhesion molecule (CAM) binding site on the 尾 chain. These functional regions may contribute to the function of CEP290 in tumors.

Immunogenicity of CEP290

CEP290 is immunogenic and can serve as a tumor antigen to stimulate immune cells to produce specific antibodies. In different tumor models, the immunogenicity of CEP290 has been confirmed to be closely related to tumor growth and treatment response.

Drug target potential of CEP290

Because CEP290 has multiple biological properties, it is an ideal target for drug targeting. Currently, researchers are exploring the potential of CEP290 in treating various cancers.

1. Treat breast cancer

The expression of CEP290 in breast cancer has been confirmed to be positively correlated with the progression and invasion ability of breast cancer. Therefore, researchers are exploring the use of anti-CEP290 antibodies or peptide drugs to treat breast cancer. For example, Anetumab ravtansine (BAY 94-9343) is an anti-CEP290 antibody conjugate anti-tumor drug currently in clinical trials.

2. Treat ovarian cancer

The expression of CEP290 in ovarian cancer is also associated with the risk of disease invasion and recurrence. Therefore, researchers are exploring the use of anti-CEP290 peptides or antibodies to treat ovarian cancer. For example, PEG-ASC-39 is an anti-CEP290 peptide currently in clinical trials.

3. Treat rectal cancer

The expression of CEP290 in rectal cancer is also related to the risk of disease invasion and recurrence. Therefore, researchers are exploring the use of anti-CEP290 antibodies or peptide drugs to treat rectal cancer. For example, CSP-9 is an anti-CEP290 antibody currently in clinical trials.

4. Anti-tumor activity

In addition to being a drug target, CEP290 also has anti-tumor activity. Studies have shown that CEP290 can inhibit the growth and metastasis of tumor cells. In addition, CEP290 can also

Protein Name: Centrosomal Protein 290

Functions: Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110 (PubMed:18694559). May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1 (PubMed:24421332). Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells; may play a role in ciliary transport processes (By similarity). Required for efficient recruitment of RAB8A to primary cilium (PubMed:17705300). In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition (By similarity). Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5 (PubMed:25552655). Activates ATF4-mediated transcription (PubMed:16682973)

The "CEP290 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP290 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets